News for ABCL Stock

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting AbCellera Reports Q1 2025 Business Results AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 AbCellera to Participate at Upcoming Investor Conferences in May and June AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 AbCellera Reports Full Year 2024 Business Results AbCellera to Participate at Upcoming Investor Conferences in March AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology AbCellera to Present at Upcoming Investor Conferences in December and January AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 AbCellera Reports Q3 2024 Business Results AbCellera to Present at Upcoming Investor Conferences in November 2024 AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 AbCellera to Present at Upcoming Investor Conferences in September AbCellera Reports Q2 2024 Business Results AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 AbCellera Reports Q1 2024 Business Results AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 AbCellera Announces Resignation of Board Member AbCellera to Present at Upcoming Investor Conferences in March AbCellera Reports Full Year 2023 Business Results AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 AbCellera Reports Q3 2023 Business Results AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023 AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology AbCellera Reports Q2 2023 Business Results AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023 DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients AbCellera Reports Q1 2023 Business Results AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023 AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023 AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023 AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023 AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023 AbCellera Reports Full Year 2022 Business Results AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 AbCellera and AbbVie Partner to Advance New Antibody Therapies AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 AbCellera Reports Q3 2022 Business Results AbCellera to Present at Upcoming Investor Conferences in November AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022 AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022 AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic AbCellera Reports Q2 2022 Business Results AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022 Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options AbCellera Reports Q1 2022 Business Results AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022 AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 AbCellera Presents Data on T Cell Engager Platform at AACR 2022 AbCellera Reports Full Year 2021 Business Results AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments AbCellera to Report Full Year 2021 Financial Results on February 24, 2022 AbCellera Announces Changes to Its Board of Directors AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12 AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer AbCellera Reports Q3 2021 Business Results AbCellera Announces Virtual Presentations at Investor Conferences in November Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19 AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021 AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19 AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference AbCellera Reports Q2 2021 Business Results EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021 AbCellera Appoints Neil Berkley as Chief Business Officer AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares AbCellera Reports Q1 2021 Business Results AbCellera to Present Virtually at Berenberg Conference on May 18, 2021 AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021 AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19 AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19 EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients AbCellera to Present at the SVB Leerink Global Healthcare Conference AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19 AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19 AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70% AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares AbCellera Announces Pricing of Initial Public Offering